These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 1122370)

  • 1. The striatonigral degenerations. Putaminal pigments and nosology.
    Borit A; Rubinstein LJ; Urich H
    Brain; 1975 Mar; 98(1):101-12. PubMed ID: 1122370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.
    Brooks DJ; Ibanez V; Sawle GV; Playford ED; Quinn N; Mathias CJ; Lees AJ; Marsden CD; Bannister R; Frackowiak RS
    Ann Neurol; 1992 Feb; 31(2):184-92. PubMed ID: 1575457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship between lipofuscin and neuromelanin in some sites of the nervous system of the horse.
    Bianchi M; Merighi A
    Exp Biol; 1986; 46(2):89-99. PubMed ID: 3817119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Striatonigral degeneration].
    Mochizuki A; Shimizu T
    Nihon Rinsho; 1997 Jan; 55(1):123-6. PubMed ID: 9014434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
    Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
    Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in nigro-striatal impairment in clinical variants of early Parkinson's disease: evidence from a FP-CIT SPECT study.
    Rossi C; Frosini D; Volterrani D; De Feo P; Unti E; Nicoletti V; Kiferle L; Bonuccelli U; Ceravolo R
    Eur J Neurol; 2010 Apr; 17(4):626-30. PubMed ID: 20050904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased iron content in the putamen of patients with striatonigral degeneration.
    Kato S; Meshitsuka S; Ohama E; Tanaka J; Llena JF; Hirano A
    Acta Neuropathol; 1992; 84(3):328-30. PubMed ID: 1414283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging.
    Ghaemi M; Hilker R; Rudolf J; Sobesky J; Heiss WD
    J Neurol Neurosurg Psychiatry; 2002 Nov; 73(5):517-23. PubMed ID: 12397143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depletion of AADC activity in caudate nucleus and putamen of Parkinson's disease patients; implications for ongoing AAV2-AADC gene therapy trial.
    Ciesielska A; Samaranch L; San Sebastian W; Dickson DW; Goldman S; Forsayeth J; Bankiewicz KS
    PLoS One; 2017; 12(2):e0169965. PubMed ID: 28166239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Striatonigral degeneration.
    Kan AE
    Pathology; 1978 Jan; 10(1):45-52. PubMed ID: 643319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A rat model of striatonigral degeneration generated by simultaneous injection of 6-hydroxydopamine into the medial forebrain bundle and quinolinic acid into the striatum.
    Yoon HH; Kim YH; Shin ES; Jeon SR
    J Korean Med Sci; 2014 Nov; 29(11):1555-61. PubMed ID: 25408589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The comparative biology of neuromelanin and lipofuscin in the human brain.
    Double KL; Dedov VN; Fedorow H; Kettle E; Halliday GM; Garner B; Brunk UT
    Cell Mol Life Sci; 2008 Jun; 65(11):1669-82. PubMed ID: 18278576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Striato-nigral degeneration (SND): a multisystem atrophy?].
    Bergmann M; Schmidtke K; Danek A; Gullotta F; Mehraein P
    Schweiz Arch Neurol Psychiatr (1985); 1990; 141(5):389-405. PubMed ID: 1701267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
    Brooks DJ; Ibanez V; Sawle GV; Quinn N; Lees AJ; Mathias CJ; Bannister R; Marsden CD; Frackowiak RS
    Ann Neurol; 1990 Oct; 28(4):547-55. PubMed ID: 2132742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Symptomatic laterality and magnetic resonance imaging (MRI) of the putamen in striatonigral degeneration (SND)].
    Yanagihara C; Ichikawa K; Kageyama Y; Satou M; Hoshino M
    Rinsho Shinkeigaku; 1994 Apr; 34(4):326-30. PubMed ID: 8026124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Striatonigral degeneration and sporadic olivopontocerebellar atrophy: a consideration of the clinical entity of multiple system atrophy].
    Miwa H; Kondo T; Mizuno Y
    No To Shinkei; 1999 Apr; 51(4):305-12. PubMed ID: 10363264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonaminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism.
    Melamed E; Hefti F; Wurtman RJ
    Ann Neurol; 1980 Dec; 8(6):558-63. PubMed ID: 6260009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease.
    Rinne JO; Ruottinen H; Bergman J; Haaparanta M; Sonninen P; Solin O
    J Neurol Neurosurg Psychiatry; 1999 Dec; 67(6):737-41. PubMed ID: 10567489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased glucose utilization in the striatum and frontal lobe in probable striatonigral degeneration.
    De Volder AG; Francart J; Laterre C; Dooms G; Bol A; Michel C; Goffinet AM
    Ann Neurol; 1989 Aug; 26(2):239-47. PubMed ID: 2789014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel grading scale for striatonigral degeneration (multiple system atrophy).
    Wenning GK; Seppi K; Tison F; Jellinger K
    J Neural Transm (Vienna); 2002 Mar; 109(3):307-20. PubMed ID: 11956953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.